CORRECTION article

Front. Oncol., 22 June 2023

Sec. Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers

Volume 13 - 2023 | https://doi.org/10.3389/fonc.2023.1233247

Corrigendum: Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis

  • Department of Hepato-Biliary-Pancreas II, Affiliated Hospital of North Sichuan Medical College, Nanchong, China

Error in Figure

In the published article, there was an error in Figure 2 as published. The two labels “Favours [LEN+TACE]” and “Favours [SOR+TACE]” located on the left and right below the X-axis, should read “Favours [SOR+TACE]” and “Favours [LEN+TACE]” respectively. The corrected Figure 2 and its caption “Forest plots for the comparison of (A) objective response rate (ORR) and disease control rate (DCR), and (B) complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD)” appear below.

Figure 2

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

hepatocellular carcinoma (HCC), lenvatinib, sorafenib (nexavar), transarterial chemoembolization (TACE), combination therapy

Citation

Liu J-N, Li J-J, Yan S, Zhang G-N and Yi P-S (2023) Corrigendum: Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Front. Oncol. 13:1233247. doi: 10.3389/fonc.2023.1233247

Received

01 June 2023

Accepted

14 June 2023

Published

22 June 2023

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

13 - 2023

Updates

Copyright

*Correspondence: Peng-Sheng Yi,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics